Drug Approval | February 10, 2025
NATCO, Lupin receive ANDA approval for Bosentan tablets for oral suspension
TFOS is indicated for the treatment of pulmonary arterial hypertension
TFOS is indicated for the treatment of pulmonary arterial hypertension
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Branded formulation business continues to perform well across domestic and export markets
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry
The company will showcase groundbreaking innovations from its Pharma and Nutrition divisions, highlighting key ingredients and formulations designed to support holistic well-being
Subscribe To Our Newsletter & Stay Updated
